GI

Limaca Medical Receives FDA 510(k) Clearance for its Breakthrough Precision GI™ Endoscopic Biopsy Device

Retrieved on: 
Monday, September 11, 2023
Pancreatic cancer, Rambam Health Care Campus, IGY, Precision, Acquisition, MD, Patient, EUS, Blood, Diagnosis, Neoplasm, FDA, GI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Biopsy, Medical device, Medical imaging

YOKNEAM, Israel, Sept. 11, 2023 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration ("FDA").

Key Points: 
  • YOKNEAM, Israel, Sept. 11, 2023 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration ("FDA").
  • This follows Limaca's receipt of FDA Breakthrough Device Designation for its Precision GI™.
  • FDA clearance allows us to bring Precision GI™ to market to fulfill our mission to always achieve precise, efficient, and definitive biopsy samples."
  • Carl Rickenbaugh, Limaca Vice Chair, added, "We are pleased with FDA's clearance of Precision GI™, following our FDA Breakthrough Device Designation.

HOYA Group PENTAX Medical supplies IRCAD with Flexible Endoscopy Systems broadening Training and Education

Retrieved on: 
Monday, September 11, 2023
Hoya Corporation, Partnership, Surgeon, Education, Training, Research, Endoscopy, Philosophy, Physician, KARL, Knowledge, Health, GI, Medtech, Nursing

TOKYO, Sept. 11, 2023 /PRNewswire/ -- HOYA Group, PENTAX Medical announced an agreement with IRCAD, the international advanced research and training center in minimally invasive surgery based in Strasbourg, France to collaborate in education for physicians to learn advanced flexible endoscopy.

Key Points: 
  • TOKYO, Sept. 11, 2023 /PRNewswire/ -- HOYA Group, PENTAX Medical announced an agreement with IRCAD, the international advanced research and training center in minimally invasive surgery based in Strasbourg, France to collaborate in education for physicians to learn advanced flexible endoscopy.
  • PENTAX Medical will supply complete flexible GI endoscopy systems to IRCAD for training and education and strengthen up the educational partnership with KARL STORZ
    "We are extremely honored to partner with IRCAD International Research and Training Center extending our own training abilities even further and to support their renowned training and education programs.
  • The partnership of IRCAD and PENTAX Medical on the training and education for physicians will be another significant step in improving patient care with minimally invasive, advanced endoscopy."
  • PENTAX Medical and KARL STORZ are living the philosophy of training and education, therefore the two companies are partnering to provide the best hands-on experience with high quality equipment at IRCAD France.

HOYA Group PENTAX Medical supplies IRCAD with Flexible Endoscopy Systems broadening Training and Education

Retrieved on: 
Monday, September 11, 2023
Hoya Corporation, Partnership, Surgeon, Education, Training, Research, Endoscopy, Philosophy, Physician, KARL, Knowledge, Health, GI, Medtech, Nursing

TOKYO, Sept. 11, 2023 /PRNewswire/ -- HOYA Group, PENTAX Medical announced an agreement with IRCAD, the international advanced research and training center in minimally invasive surgery based in Strasbourg, France to collaborate in education for physicians to learn advanced flexible endoscopy.

Key Points: 
  • TOKYO, Sept. 11, 2023 /PRNewswire/ -- HOYA Group, PENTAX Medical announced an agreement with IRCAD, the international advanced research and training center in minimally invasive surgery based in Strasbourg, France to collaborate in education for physicians to learn advanced flexible endoscopy.
  • PENTAX Medical will supply complete flexible GI endoscopy systems to IRCAD for training and education and strengthen up the educational partnership with KARL STORZ
    "We are extremely honored to partner with IRCAD International Research and Training Center extending our own training abilities even further and to support their renowned training and education programs.
  • The partnership of IRCAD and PENTAX Medical on the training and education for physicians will be another significant step in improving patient care with minimally invasive, advanced endoscopy."
  • PENTAX Medical and KARL STORZ are living the philosophy of training and education, therefore the two companies are partnering to provide the best hands-on experience with high quality equipment at IRCAD France.

Acupath Laboratories Inc. Launches the BioFire® FilmArray® Gastrointestinal Pathogen (GI) Panel

Retrieved on: 
Thursday, September 7, 2023
Gastroenteritis, FDA, Health, Research, Patient, GI, PCR, Medical imaging

PLAINVIEW, N.Y., Sept. 7, 2023 /PRNewswire/ -- Acupath Labs a leading provider of sub-specialized anatomic and molecular pathology services, launches the BioFire® FilmArray® GI Panel, a FDA-cleared PCR based panel that tests for 22 of the most common pathogens associated with gastroenteritis, with results in ~ 1 hour.   

Key Points: 
  • Acupath Labs Launches a PCR Based Gastrointestinal Pathogen (GI) Panel the BioFire® FilmArray® with Results in 24 Hours.
  • With an overall sensitivity of 98.5% and Specificity of 99.2%, the BioFire® FilmArray® GI Panel represents a significant leap forward in patient care.
  • Traditional molecular testing, while valuable in many contexts, has some limitations that newer technologies aim to address," says Brian Kunkel, Chief Operating Officer of Acupath.
  • For information on how to order the BioFire® FilmArray® Gastrointestinal Pathogen (GI) Panel, email [email protected] .

Curio Wellness Joins with Real Housewives Star in Exclusive Cannabis Partnership

Retrieved on: 
Wednesday, September 6, 2023
Real, Curio, Partnership, Dixie, Housewife, Pain, Insomnia, Patient, Cannabis, Health, The Real Housewives of Potomac, GI, The Real Housewives, Medicinals, Transformer, Drug

TIMONIUM, Md., Sept. 6, 2023 /PRNewswire/ -- Curio Wellness, a cGMP-certified, vertically integrated cannabis company and market-leading innovator of health and wellness products, today announced an exclusive partnership with Eddie Osefo of The Real Housewives of Potomac, to launch his new cannabis product line Happy Eddie in Maryland. The line will include flower and pre-rolls, available at Curio Wellness-owned Far & Dotter and Pharmkent dispensaries, and additional dispensaries across the state.

Key Points: 
  • Maryland cannabis leader Curio Wellness to launch "Happy Eddie" brand, founded by Eddie Osefo of The Real Housewives of Potomac
    TIMONIUM, Md., Sept. 6, 2023 /PRNewswire/ -- Curio Wellness , a cGMP-certified, vertically integrated cannabis company and market-leading innovator of health and wellness products, today announced an exclusive partnership with Eddie Osefo of The Real Housewives of Potomac, to launch his new cannabis product line Happy Eddie in Maryland.
  • Happy Eddie was founded in 2023 by Eddie Osefo, Real Housewives of Potomac husband, attorney and entrepreneur, alongside Brian Albanese and Eric Brady.
  • The "Happy Eddie" brand name was inspired by Osefo's Real Housewives viral moment on the show last year.
  • Curio Wellness is a leader in cannabis and wellness, offering a wide variety of products specifically developed to aid conditions like pain, GI issues , insomnia and more.

Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 6, 2023
General Health, Genetics, Health, Gastrointestinal disease, CRC, IBD, MBA, Research, RNA, Inflammatory bowel disease, Incidence, PMA, Patient, Colorectal cancer, Medicine, Morgan, FDA, GI, Conference, Food, Pharmaceutical industry

Geneoscopy Inc. , a life sciences company focused on developing diagnostic tests for gastrointestinal health, today announced that Chief Executive Officer and Co-founder Andrew Barnell, MBA, will be presenting at the Morgan Stanley Global Healthcare Conference in New York, NY, on Monday, Sept. 11, at 2:15 p.m. Eastern Time.

Key Points: 
  • Geneoscopy Inc. , a life sciences company focused on developing diagnostic tests for gastrointestinal health, today announced that Chief Executive Officer and Co-founder Andrew Barnell, MBA, will be presenting at the Morgan Stanley Global Healthcare Conference in New York, NY, on Monday, Sept. 11, at 2:15 p.m. Eastern Time.
  • In addition, a recent study found that nearly 1 in 100 Americans suffer from IBD, with an estimated 2.39 million diagnosed.
  • “We are pleased to be presenting at Morgan Stanley’s Annual Global Healthcare Conference to share the promising market opportunities for our proprietary RNA biomarker platform and high-value diagnostic tests,” said Andrew Barnell, CEO and Co-founder of Geneoscopy.
  • These results are the highest reported for any noninvasive CRC screening test in any prospective registrational clinical study completed to date.

One GI® Appoints Christa Newton as Chief Executive Officer

Retrieved on: 
Tuesday, September 5, 2023
Newton, Communication, Partnership, Gastroenterology, Culture, People First, Mergers & Acquisitions, Medicine, Multimedia, Physician, Mergers and acquisitions, MSO, Health, GI, Management, Pharmaceutical industry

NASHVILLE, Tenn., Sept. 5, 2023 /PRNewswire/ -- One GI®, a management service organization (MSO) specializing in gastroenterology, is pleased to introduce Christa Newton as its new Chief Executive Officer (CEO).

Key Points: 
  • NASHVILLE, Tenn., Sept. 5, 2023 /PRNewswire/ -- One GI®, a management service organization (MSO) specializing in gastroenterology, is pleased to introduce Christa Newton as its new Chief Executive Officer (CEO).
  • Christa previously served One GI® as the Chief Operating Officer.
  • As COO, Christa has become a trusted leader to our physician partners and embodies the values and culture central to our organization.
  • Christa brings a wealth of experience in propelling organizations toward heightened performance, seamless integration, and robust revenue growth.

United Digestive Transitions Endoscopy Centers to Provation® Apex Platform

Retrieved on: 
Thursday, August 31, 2023
Software, Biotechnology, Practice Management, General Health, Health, Data Management, Health Technology, Technology, Software as a service, Gastroenterology, UD, FTV, Pathology, Provat Lakra, Fortive, Documentation, Patient, Growth, Digestive, GI, NYSE, Nursing

“United Digestive embraces a cloud-first strategy that supports our rapid growth as an organization,” said Mark Gilreath, CEO of United Digestive.

Key Points: 
  • “United Digestive embraces a cloud-first strategy that supports our rapid growth as an organization,” said Mark Gilreath, CEO of United Digestive.
  • “Provation Apex was a clear choice enabling our entire care team to document procedures on one platform.
  • UD has chosen to adopt the entire platform, including solutions and features for physician and nursing documentation, patient engagement, document management, interfaces, pathology, and enterprise reporting.
  • “United Digestive is cutting-edge,” said Ankush Kaul, President of Provation.

i2o Therapeutics Names Kurt Graves Chairman and CEO, Announces Corporate Updates

Retrieved on: 
Monday, August 28, 2023
Health, Diabetes, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Executive, Obesity, Prevalence, Harvard University, The Conference Board, Intarcia Therapeutics, Disability, EVP, Policy, Intarsia, PYY, Ionic liquid, IP, Glucagon, Medication, Novartis, Acquisition, Omeprazole, Vertex Pharmaceuticals, ITCA, Merck, Commercial, Therapy, Lancet, Death, House of Medici, Society, GI, Peptide, Disease, Corporate development, Pharmaceutical industry

i2o Therapeutics, Inc. today announced the appointment of Kurt Graves as Chairman, President and CEO.

Key Points: 
  • i2o Therapeutics, Inc. today announced the appointment of Kurt Graves as Chairman, President and CEO.
  • Mr. Graves succeeds i2o co-founder and CEO Ravi Srinivasan, Ph.D., who is pursuing other leadership opportunities within the life sciences field.
  • He has previously served as Chairman, President and CEO of Intarcia Therapeutics, former Chairman of Radius Health, former Executive Chairman of i2o Therapeutics, and as a Board member at Achillion Pharmaceuticals until it was acquired, and at Seres Health.
  • Previously, Mr. Graves served as EVP, Head of Corporate Development, Strategic Drug Development and Program Management and Head of Commercial at Vertex Pharmaceuticals.

EffectiCal's Exceptional Efficacy as a Calcium Supplement

Retrieved on: 
Monday, August 28, 2023
Food, Zinc, Gastrointestinal tract, Osteoporosis, Magnesium, Johns Hopkins University, Constipation, Woman, Abdominal pain, Calcium, National Institute for Health and Care Excellence, Risk, Kidney, Menopause, D3, Bloating, Vitamin D, Health effects of sunlight exposure, GI, NIH, Dietary supplement

FORT LAUDERDALE, Fla., Aug. 28, 2023 /PRNewswire/ -- Calcium supplements are common. Many Americans fail to achieve the recommended daily dose of calcium through their diets and seek to make up that deficit through a supplement. NIH reports that 32% of women, in particular, take a dietary supplement containing calcium. The National Institute of Health adds that between foods and supplements, the average woman gets around 1009 mg of calcium each day.

Key Points: 
  • Sinoveda's Innovative Calcium Supplement Is a Safe, Efficient, and Effective Way to Preserve Bone Health and Prevent Osteoporosis
    FORT LAUDERDALE, Fla., Aug. 28, 2023 /PRNewswire/ -- Calcium supplements are common.
  • Many Americans fail to achieve the recommended daily dose of calcium through their diets and seek to make up that deficit through a supplement.
  • NIH reports that 32% of women , in particular, take a dietary supplement containing calcium.
  • EffectiCal stands out as a calcium supplement for a few key reasons:
    A single dose consists of a complex mixture that includes calcium, vitamin D, magnesium, and zinc.